Core Viewpoint - Wanbangde's subsidiary has developed a new drug, "Shisuanjianma Controlled-release Tablets," for treating mild to moderate Alzheimer's disease, which has completed the enrollment of 100 subjects in its critical II/III phase clinical trial [1] Group 1: Drug Development - The new drug is characterized by a dual-phase controlled-release technology that stabilizes the drug release curve, prolongs the release time in the body, and aims to reduce adverse reactions while enhancing dosage safety [1] - The clinical trial is led by the Capital Medical University Xuanwu Hospital, with Professor Jia Jianping, a leading expert in the field of neurology, overseeing the project in collaboration with over 50 top research centers nationwide [1] Group 2: Research and Collaboration - The drug has been selected for the National Science and Technology Major Project for Innovative Drug Development, highlighting its significance in utilizing local resources, as its active ingredient is derived from the traditional Chinese medicinal plant, Qianshengtang (Sarcandra glabra) [1] - Wanbangde is steadily advancing the subject enrollment process and will continue close collaboration with Xuanwu Hospital and other research institutions to further validate the drug's safety and efficacy, providing critical data support for future market application [1]

Hot Topics - Jia Mei Packaging's stock trading suspension review has concluded, and the stock will resume trading tomorrow [1] - Fenglong Co., Ltd.'s stock trading suspension review has concluded, and the stock will resume trading tomorrow [2] - Hongbaoli does not produce epoxy propylene products, and its subsidiary's related project has entered the preliminary preparation stage for trial production [2] - Hunan Gold's future market price for gold products has uncertainty regarding whether it can continue to rise or maintain high levels [2] - Tongding Interconnection's current operating conditions are normal, with no significant changes in the internal and external operating environment [3] - Tiandi Online's recent operating conditions and internal and external operating environment show no significant changes [4] - Dayue City reports no significant changes in its recent operating conditions and internal and external environment [5] - Huangtai Liquor Industry is not involved in hot concept matters, and its current operating conditions are normal [6] Performance - Leshan Electric Power reported a net profit of 23.4023 million yuan for 2025, an increase of 3.68% year-on-year [7] - Great Wall Motors sold 90,300 vehicles in January, a year-on-year increase of 11.59% [8] - Seres sold 45,900 vehicles in January, a year-on-year increase of 104.85% [9] - GAC Group sold 116,600 vehicles in January, a year-on-year increase of 18.47% [10] - BAIC Blue Valley's subsidiary sold 8,073 vehicles in January, a year-on-year increase of 11.83% [11] Shareholding Changes - Chipone Technology's shareholders plan to reduce their holdings by no more than 1.95% of the company's shares [30] Share Buybacks - Chuzhou Dongfeng's controlling shareholder proposed to repurchase shares worth 50 million to 100 million yuan [31] - GoerTek has increased the total amount for share repurchase from no less than 500 million yuan (inclusive) and no more than 1 billion yuan (inclusive) to no less than 1 billion yuan (inclusive) and no more than 1.5 billion yuan (inclusive) [31] Contract Awards - Jerry Holdings' wholly-owned subsidiary signed a sales contract for gas turbine generator sets worth approximately 1.265 billion yuan with a U.S. client [32] - Fulongma is expected to win four sanitation service projects in January, with a total first-year service fee of 83.5364 million yuan [34] Equity Changes - Yanzhou Coal Mining is transferring 100% equity of Xintai Coal [33] Mergers and Acquisitions - BGI Genomics plans to acquire 100% equity of Sanjian Qifa and 100% equity of BGI Xufeng to integrate two cutting-edge technology platforms in spatial omics and nanopore sequencing [34] Refinancing - Sanjia Technology (rights protection) plans to issue shares to its controlling shareholder to raise no more than 300 million yuan for working capital and repaying bank loans [35] Other - Fushikong's actual controller, chairman, and general manager Chen Yongliang has been placed under detention [36] - China Mobile's VAT tax category adjustment will change the applicable VAT rate from 6% to 9% [37] - China Telecom's VAT tax category adjustment will impact the company's revenue and profits [38] - China Unicom's VAT tax category adjustment will change the applicable VAT rate from 6% to 9% [39] - Nanwang Energy's price policy adjustment for pumped storage and new energy storage will increase uncertainty in revenue and profits from pumped storage power stations [39] - Wanbangde has completed the enrollment of 100 subjects for the clinical trials of Shishan Jianjia controlled-release tablets phases II and III [39] - Penghui Energy has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange [40] - Haichuang Pharmaceutical has passed the GMP compliance inspection for drugs [41]

Core Viewpoint - The company has completed the enrollment of 100 subjects for the Phase II/III clinical trial of Huperzine A Controlled-Release Tablets, a new drug for treating mild to moderate Alzheimer's disease, indicating progress in its drug development efforts [1][3]. Group 1: Product Information - Product Name: Huperzine A Controlled-Release Tablets - Drug Classification: Category 2.2 new drug - Indication: Mild to moderate Alzheimer's disease - Dosage Form: Tablet, 0.2mg [1][2] - The drug is a cholinesterase inhibitor aimed at improving cognitive function, showing potential in preclinical studies to slow the progression of Alzheimer's disease and offering various benefits, including reducing β-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects [1]. Group 2: Clinical Trial Details - The company is collaborating with over 50 research institutions nationwide, including Capital Medical University Xuanwu Hospital, to further validate the drug's safety and efficacy [3]. - The controlled-release technology allows for a smoother drug release profile, enhancing patient convenience and adherence by supporting once-daily dosing [2].

Group 1 - The core announcement is that Wanbangde (002082) has completed the enrollment of 100 subjects for its Phase II/III pivotal registration clinical trial of the new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia [1] Group 2 - The drug is classified as a Class 2 new drug, indicating its potential significance in the pharmaceutical market [1] - The trial's completion of subject enrollment marks a critical step in the drug's development process, which could lead to future commercialization [1]

Core Viewpoint - Wanbangde (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has completed the enrollment of 100 subjects for the Phase II/III pivotal registration clinical trial of its Class 2 new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia [1] Group 1 - Huperzine A is a cholinesterase inhibitor used to improve cognitive function, showing potential in preclinical studies to delay the progression of Alzheimer's disease and offering broad benefits, including the reduction of beta-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects [1] - The company is actively advancing subject enrollment and will continue to collaborate closely with over 50 research institutions nationwide, including Xuanwu Hospital of Capital Medical University, to further validate the drug's safety and efficacy [1] - The data obtained from this trial will provide critical support for the drug's final market application [1]

证券代码：002082 证券简称：万邦德 公告编号：2026-008 规格：0.2mg 注册分类：2.2 类新药 万邦德医药控股集团股份有限公司 关于石杉碱甲控释片 II/III 期临床试验 完成 100 例受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司的 2.2 类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病 型痴呆的 II/III 期关键注册临床试验，于近日完成 100 例受试者入组。现将相 关情况公告如下： 一、产品基本情况 名称：石杉碱甲控释片 英文名称：Huperzine A Controlled-Release Tablets 剂型：片剂 本试验受试者入组短期内不会对公司经营业绩产生重大影响，公司将按照相 关规定和要求继续开展临床试验。药品研发具有高投入、高风险、长周期等特点， 临床试验进度及结果、未来产品市场竞争形势均存在不确定性。公司将积极推进 上述项目，并严格按照有关规定对后续进展履行信披义务。敬请广大投资者注意 投资风险。 特此公告。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公司已就业绩预告有关事项与会计师事务所进行预先沟通，公司 与会计师事务所在业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司受国家药品、医疗器械招标、集采政策持续推进的影响，集采覆盖区域的进一步扩大，公司相 关产品集采后价格下降明显，行业市场竞争加剧，在第十批国家集采中有产品未能中标，造成公司利润 大幅度下降。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为负值 单位：万元 ■ 本次业绩预告是公司财务部门初步测算的结果，具体财务数据以公司披露的《2025年年度报告》为准。 敬请广大投资者谨慎决策，注意投资风险。 特此公告。 万邦德医药控股集团股份有限公司 董事会 2026年1月31日 2、公司由仿制药向创新药战略发展转型升级，加速创新药全球研发力度，研发投入加大。 3、公司创新药国际化制剂车间、原料药基地、中非医疗科技园国际 ...

南财智讯1月30日电，万邦德发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-17,000万元—-9,000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-18,000万元—-10,000万元。业绩变动原因说明：1、公司受国家药品、医疗器械招标、集采政策持续 推进的影响，集采覆盖区域的进一步扩大，公司相关产品集采后价格下降明显，行业市场竞争加剧，在 第十批国家集采中有产品未能中标，造成公司利润大幅度下降；2、公司由仿制药向创新药战略发展转 型升级，加速创新药全球研发力度，研发投入加大；3、公司创新药国际化制剂车间、原料药基地、中 非医疗科技园国际化标准的器械车间投入大，投入使用的固定资产折旧增加，但尚未形成规模效应； 4、报告期内，高分子产品生产厂区整体异地搬迁，影响医疗器械产品的生产与市场供应。 ...

证券代码：002082 证券简称：万邦德 公告编号：2026-007 万邦德医药控股集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公司已就业绩预告有关事项与会计 师事务所进行预先沟通，公司与会计师事务所在业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司受国家药品、医疗器械招标、集采政策持续推进的影响，集采覆 盖区域的进一步扩大，公司相关产品集采后价格下降明显，行业市场竞争加剧， 在第十批国家集采中有产品未能中标，造成公司利润大幅度下降。 2、公司由仿制药向创新药战略发展转型升级，加速创新药全球研发力度， 研发投入加大。 3、公司创新药国际化制剂车间、原料药基地、中非医疗科技园国际化标 准的器械车间投入大，投入使用的固定资产折旧增加，但尚未形成规模效应。 4、报告期内，高分子产品生产厂区整体异地搬迁，影响医疗器械产品的 生产与市场供应。 2 ...

特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、会议召开时间 1）现场会议时间：2026年1月28日下午14:00。 登录新浪财经APP 搜索【信披】查看更多考评等级 2）网络投票时间：通过深圳证券交易所交易系统进行投票的时间为2026年1月28日上午9:15-9:25，9:30- 11:30，下午13:00-15:00；通过深圳证券交易所互联网系统进行投票的时间为2026年1月28日上午9:15至 下午15:00期间的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 会议的召集、召开及表决程序符合《公司法》等相关法律法规及部门规章和《公司章程》等有关规定。 二、会议出席情况 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简称"公司"）董事会 4、会议主持人：董事长赵守明先生。 1.出席本次股东会的股东或股东代理人共计184人，代表有表决权的股份数312,636,981股，占公司有表 决权总股 ...